GURUFOCUS.COM » STOCK LIST » Technology » Software » Synopsys Inc (NAS:SNPS) » Definitions » PE Ratio without NRI
中文

Synopsys (Synopsys) PE Ratio without NRI : 46.24 (As of Apr. 25, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Synopsys PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-04-25), Synopsys's share price is $527.52. Synopsys's EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2024 was $11.41. Therefore, Synopsys's PE Ratio without NRI for today is 46.24.

During the past 13 years, Synopsys's highest PE Ratio without NRI was 68.00. The lowest was 20.64. And the median was 39.68.

Synopsys's EPS without NRI for the three months ended in Jan. 2024 was $3.56. Its EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2024 was $11.41.

As of today (2024-04-25), Synopsys's share price is $527.52. Synopsys's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $9.08. Therefore, Synopsys's PE Ratio for today is 58.10.

During the past years, Synopsys's highest PE Ratio was 333.93. The lowest was 22.43. And the median was 40.80.

Synopsys's EPS (Diluted) for the three months ended in Jan. 2024 was $2.89. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $9.08.

Synopsys's EPS (Basic) for the three months ended in Jan. 2024 was $2.95. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2024 was $9.25.


Synopsys PE Ratio without NRI Historical Data

The historical data trend for Synopsys's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synopsys PE Ratio without NRI Chart

Synopsys Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.43 48.46 66.93 46.21 41.95

Synopsys Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.17 52.09 52.68 41.95 46.75

Competitive Comparison of Synopsys's PE Ratio without NRI

For the Software - Infrastructure subindustry, Synopsys's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synopsys's PE Ratio without NRI Distribution in the Software Industry

For the Software industry and Technology sector, Synopsys's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Synopsys's PE Ratio without NRI falls into.



Synopsys PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Synopsys's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=527.52/11.409
=46.24

Synopsys's Share Price of today is $527.52.
Synopsys's EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.41.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Synopsys  (NAS:SNPS) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Synopsys PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of Synopsys's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Synopsys (Synopsys) Business Description

Address
675 Almanor Avenue, Sunnyvale, CA, USA, 94085
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Executives
Mercedes Johnson director MICRON TECHNOLOGY, INC, 8000 S FEDERAL WAY, MS 1-557, BOISE ID 83716
Richard S. Mahoney officer: Chief Revenue Officer 2600 ANSYS DRIVE, CANONSBURG PA 15317
Runkel John F Jr officer: General Counsel & C/O INTUITIVE SURGICAL, INC., 1266 KIFER ROAD, SUNNYVALE CA 94086
Sudhindra Kankanwadi officer: VP and Corporate Controller 690 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Robert G Painter director C/O TRIMBLE INC., 935 STEWART DRIVE, SUNNYVALE CA 94085
Geus Aart De director, officer: Chairman of the Board & Co-CEO
Sassine Ghazi officer: Chief Operating Officer 3075 W RAY ROAD, SUITE 528, THE PARK AT SAN TAN, CHANDLER AZ 85226
Shelagh Glaser officer: CFO ZENDESK, INC., 989 MARKET STREET, SAN FRANCISCO CA 94103
Roy Vallee director 2211 S 47TH ST, PHOENIX AZ 85034
Joseph W Logan officer: EVP, Sales & Corp Marketing 700 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Chrysostomos L Nikias director UNIVERSITY OF SOUTHERN CALIFORNIA, 3551 TROUSEDALE, BOVARD ADM 102, LOS ANGELES CA 90089-4019
Trac Pham officer: CFO 700 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Luis Borgen director 58 SUNSET RIDGE LANE, BOLTON MA 01740
Marc N Casper director C/O THERMO FISHER SCIENTIFIC, 168 THIRD AVENUE, WALTHAM MA 02451
Chi-foon Chan director, officer: Co-CEO & President

Synopsys (Synopsys) Headlines